Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense ABVD for early unfavourable or advanced Hodgkin lymphoma
ACTRN12612000137897Phase 2Not yet recruiting
- Sponsor
- Queensland Health
- Start
- Mar 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of doxorubicin, bleomycin, vinblastine, dacarbazine and filgrastim in Hodgkin lymphoma (HL) (2 arms), sponsored by Queensland Health. Primary endpoints: Feasibility and safety: on-time completion without severe hematologic toxicity and Bleomycin lung toxicity. Planned start Mar 2012; status: not yet recruiting.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazinefilgrastim
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on ACTRN12612000137897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000137897.